title: STALing B cell responses with CD22.
abstract: Suppressing unwanted humoral immune responses without compromising the host's ability to respond to foreign pathogens is a primary goal for therapies aimed at ameliorating harmful autoantibody production. Global suppression of the immune system via lymphocyte depletion and/or immunosuppressive drugs can have off-target effects, a limitation to conventional therapies. In this issue of the JCI, Macauley and colleagues utilize a novel platform to inhibit antigen-specific antibody production that preserves the immune system's ability to respond to unrelated antigens.
authors.affiliation: Department of Immunology, University of Washington, Seattle, Washington 98195, USA.
authors.forename: Craig P
authors.initials: CP
authors.lastname: Chappell
authors.forename: Edward A
authors.initials: EA
authors.lastname: Clark
mesh_terms: D000818:Animals; D017209:Apoptosis; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D008081:Liposomes / Q000276:immunology*; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000502:physiology*
chemical_list: C497868:Cd22 protein, mouse; D008081:Liposomes; D051918:Sialic Acid Binding Ig-like Lectin 2